Scholarlink

Background <p>The real-world comparative effectiveness study aimed to compare the effectiveness of vonoprazan (VON)-based therapy with high-dose esomeprazole (ESO)-based therapy in the re-eradication of <i>Helicobacter pylori</i>.</p> Methods <p>This real-world retrospective study analyzed patients at Nanjing First Hospital undergoing <i>H</i>. <i>pylori</i> re-eradication, who received either vonoprazan-based (VON) or high-dose esomeprazole-based (ESO) quadruple therapy. Both regimens included amoxicillin, furazolidone, and bismuth, administered twice daily for 14 days. Treatment strategies were determined by routine clinical practice, using either culture results or local epidemiological data. Patients were further classified into individualized precision (VON-P, ESO-P) or empirical (VON-E, ESO-E) groups based on real-world clinical decision-making.</p> Results <p>The <i>H</i>. <i>pylori</i> re-eradication rates were 89.2% (191/214, 95% CI: 84.4–92.7%) in group ESO and 86.0% (98/114, 95% CI: 78.4–91.2%) in group VON, with no statistically significant difference between groups (<i>P</i> = 0.381). Among patients receiving individualized precision treatment, the re-eradication rates were 87.3% (62/71, 95%CI: 77.6–93.2%) for group ESO-P and 86.9% (53/61, 95% CI: 76.2–93.2%) for group VON-P, with no significant difference observed (<i>P</i> = 0.940). Similarly, for patients undergoing empirical treatment, there was no statistically significant difference in re-eradication rates between group ESO-E and group VON-E (90.2%, 129/143, 95% CI: 84.2–94.1% vs. 84.9%, 45/53, 95% CI: 72.9–92.1%; <i>P</i> = 0.296). Additionally, no significant difference was found between group ESO-E and group ESO-P (90.2%, 129/143, 95% CI: 84.2–94.1% vs. 87.3%, 62/71, 95% CI: 77.6–93.2%; <i>P</i> = 0.521), nor between group VON-E and group VON-P (84.9%, 45/53, 95% CI: 72.9–92.1% vs. 86.9%, 53/61, 76.2–93.2%; <i>P</i> = 0.762).</p> Conclusions <p>Both high-dose esomeprazole-containing quadruple therapy and VON-containing quadruple therapy have demonstrated effective as rescue treatments for <i>H</i>. <i>pylori</i> infection. Additionally, antibiotic selection informed by local epidemiological data demonstrated comparable effective to culture-based methods in this cohort, though future large-scale studies are needed to validate its generalizability.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Vonoprazan vs. high-dose esomeprazole in bismuth-containing quadruple therapy for Helicobacter pylori rescue treatment: a retrospective cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月26日

查看全文
  • Xuetian Qian,
  • Bo Gao,
  • Zhenqiu Chen,
  • Zhenyu Zhang,
  • Zongdan Jiang

摘要

Background

The real-world comparative effectiveness study aimed to compare the effectiveness of vonoprazan (VON)-based therapy with high-dose esomeprazole (ESO)-based therapy in the re-eradication of Helicobacter pylori.

Methods

This real-world retrospective study analyzed patients at Nanjing First Hospital undergoing H. pylori re-eradication, who received either vonoprazan-based (VON) or high-dose esomeprazole-based (ESO) quadruple therapy. Both regimens included amoxicillin, furazolidone, and bismuth, administered twice daily for 14 days. Treatment strategies were determined by routine clinical practice, using either culture results or local epidemiological data. Patients were further classified into individualized precision (VON-P, ESO-P) or empirical (VON-E, ESO-E) groups based on real-world clinical decision-making.

Results

The H. pylori re-eradication rates were 89.2% (191/214, 95% CI: 84.4–92.7%) in group ESO and 86.0% (98/114, 95% CI: 78.4–91.2%) in group VON, with no statistically significant difference between groups (P = 0.381). Among patients receiving individualized precision treatment, the re-eradication rates were 87.3% (62/71, 95%CI: 77.6–93.2%) for group ESO-P and 86.9% (53/61, 95% CI: 76.2–93.2%) for group VON-P, with no significant difference observed (P = 0.940). Similarly, for patients undergoing empirical treatment, there was no statistically significant difference in re-eradication rates between group ESO-E and group VON-E (90.2%, 129/143, 95% CI: 84.2–94.1% vs. 84.9%, 45/53, 95% CI: 72.9–92.1%; P = 0.296). Additionally, no significant difference was found between group ESO-E and group ESO-P (90.2%, 129/143, 95% CI: 84.2–94.1% vs. 87.3%, 62/71, 95% CI: 77.6–93.2%; P = 0.521), nor between group VON-E and group VON-P (84.9%, 45/53, 95% CI: 72.9–92.1% vs. 86.9%, 53/61, 76.2–93.2%; P = 0.762).

Conclusions

Both high-dose esomeprazole-containing quadruple therapy and VON-containing quadruple therapy have demonstrated effective as rescue treatments for H. pylori infection. Additionally, antibiotic selection informed by local epidemiological data demonstrated comparable effective to culture-based methods in this cohort, though future large-scale studies are needed to validate its generalizability.